The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to β-lactams in a large teaching hospital

被引:29
作者
Regal, RE
DePestel, DD
VandenBussche, HL
机构
[1] Univ Michigan, Hlth Syst, Dept Pharm Serv, UH B2D301, Ann Arbor, MI 48109 USA
[2] Coll Pharm, Ann Arbor, MI 48109 USA
来源
PHARMACOTHERAPY | 2003年 / 23卷 / 05期
关键词
D O I
10.1592/phco.23.5.618.32197
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objectives. To compare the use of beta-lactams and subsequent Pseudomonas aeruginosa sensitivity patterns before and after implementation of a clinical pharmacist-facilitated antimicrobial restriction program in August 1997. Design. Retrospective consecutive data collection. Setting. Large university-affiliated medical center. Intervention. The study results are the accumulation of the daily intervention activities of the antimicrobial restriction program. Data on antimicrobial grams purchased/1000 patient-days and susceptibility patterns were collected and analyzed retrospectively. Measures and Main Results. Annual grams of ceftazidime, piperacillin, piperacillin-tazobactam, and other antipseudomonal beta-lactams purchased/1000 patient-days were compared during the 2 full calendar years before the antimicrobial restriction program (1995-1996) with the 4 full calendar years after the program was implemented (1998-2001). Pseudomonas aeruginosa resistance trends for the antipseudomonal beta-lactams, ciprofloxacin, and tobramycin also were compared for the 2 years before the program (1995-1996) with the last 2 years of the program (2000-2001). A 44% reduction in ceftazidime use was documented; ostensibly, minimal changes occurred in the overall use of piperacillin and piperacillin-tazobactam. During the same time period, ceftazidime resistance fell from 24% to 11.8% (p<0.001), whereas piperacillin resistance fell from 32.5% to 18.5% (p<0.001). Imipenem resistance declined from 20.5% to 12.3% (p<0.001) with an 18% reduction in use. Aztreonam resistance declined from 29.5% to 16.5% (p<0.001) despite a 57% increase in use. No changes in resistance to either ciprofloxacin or tobramycin were found. Conclusion. Through an antimicrobial restriction program, a dramatic reduction in ceftazidime use was achieved with judicious use of other antipseudomonal antimicrobials, which resulted in reduced resistance of P aeruginosa to other beta-lactams.
引用
收藏
页码:618 / 624
页数:7
相关论文
共 25 条
[1]  
[Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P1
[2]   The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage [J].
Bradley, SJ ;
Wilson, ALT ;
Allen, MC ;
Sher, HA ;
Goldstone, AH ;
Scott, GM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (02) :261-266
[3]   Antibiotic resistance - Squeezing the balloon? [J].
Burke, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (14) :1270-1271
[4]   Effect of β-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa [J].
Carsenti-Etesse, H ;
Cavallo, JD ;
Roger, PM ;
Ziha-Zarifi, I ;
Plesiat, P ;
Garrabe, E ;
Dellamonica, P .
CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 (03) :144-151
[5]   The problem with cephalosporins [J].
Dancer, SJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (04) :463-478
[6]   The effect of an antimicrobial formulary change on hospital resistance patterns [J].
Empey, KM ;
Rapp, RP ;
Evans, ME .
PHARMACOTHERAPY, 2002, 22 (01) :81-87
[7]  
GRIMM H, 1984, ARZNEIMITTELFORSCH, V34-1, P62
[8]   Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary [J].
Landman, D ;
Chockalingam, M ;
Quale, JM .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) :1062-1066
[9]   β-lactamase inhibitor combinations with extended-spectrum penicillins:: Factors influencing antibacterial activity against Enterobacteriaceae and Pseudomonas aeruginosa [J].
Lister, PD .
PHARMACOTHERAPY, 2000, 20 (09) :213S-218S
[10]   Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa:: Our worst nightmare? [J].
Livermore, DM .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :634-640